0PT Stock Overview
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States.
Notes are coming soon
Prothena Corporation plc Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$50.22|
|52 Week High||US$64.54|
|52 Week Low||US$21.60|
|1 Month Change||-6.24%|
|3 Month Change||-15.79%|
|1 Year Change||65.20%|
|3 Year Change||305.00%|
|5 Year Change||47.71%|
|Change since IPO||924.90%|
Recent News & Updates
|0PT||DE Biotechs||DE Market|
Return vs Industry: 0PT exceeded the German Biotechs industry which returned 13.9% over the past year.
Return vs Market: 0PT exceeded the German Market which returned -8.7% over the past year.
|0PT Average Weekly Movement||8.3%|
|Biotechs Industry Average Movement||5.4%|
|Market Average Movement||5.2%|
|10% most volatile stocks in DE Market||10.2%|
|10% least volatile stocks in DE Market||2.3%|
Stable Share Price: 0PT is more volatile than 75% of German stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: 0PT's weekly volatility has decreased from 15% to 8% over the past year, but is still higher than 75% of German stocks.
About the Company
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson’s disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer’s disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer’s disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer’s disease.
Prothena Corporation plc Fundamentals Summary
|0PT fundamental statistics|
Is 0PT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|0PT income statement (TTM)|
|Cost of Revenue||US$120.75m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-3.03|
|Net Profit Margin||-3,036.03%|
How did 0PT perform over the long term?See historical performance and comparison